These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 33254510)

  • 21. TLR7 is a key regulator of innate immunity against Japanese encephalitis virus infection.
    Nazmi A; Mukherjee S; Kundu K; Dutta K; Mahadevan A; Shankar SK; Basu A
    Neurobiol Dis; 2014 Sep; 69():235-47. PubMed ID: 24909816
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bioinformatic analysis and identification of single-stranded RNA sequences recognized by TLR7/8 in the SARS-CoV-2, SARS-CoV, and MERS-CoV genomes.
    Moreno-Eutimio MA; López-Macías C; Pastelin-Palacios R
    Microbes Infect; 2020; 22(4-5):226-229. PubMed ID: 32361001
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Topical imiquimod has therapeutic and immunomodulatory effects against intracranial tumors.
    Xiong Z; Ohlfest JR
    J Immunother; 2011 Apr; 34(3):264-9. PubMed ID: 21389872
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interactions between TLR7 and TLR9 agonists and receptors regulate innate immune responses by astrocytes and microglia.
    Butchi NB; Du M; Peterson KE
    Glia; 2010 Apr; 58(6):650-64. PubMed ID: 19998480
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-hepatitis B virus (HBV) response of imiquimod based toll like receptor 7 ligand in hbv-positive human hepatocelluar carcinoma cell line.
    Das D; Sengupta I; Sarkar N; Pal A; Saha D; Bandopadhyay M; Das C; Narayan J; Singh SP; Chakrabarti S; Chakravarty R
    BMC Infect Dis; 2017 Jan; 17(1):76. PubMed ID: 28088184
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Repurposing prolactin as a promising immunomodulator for the treatment of COVID-19: Are common Antiemetics the wonder drug to fight coronavirus?
    Sen A
    Med Hypotheses; 2020 Nov; 144():110208. PubMed ID: 33254515
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Toll-like Receptor Mediation in SARS-CoV-2: A Therapeutic Approach.
    Manan A; Pirzada RH; Haseeb M; Choi S
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142620
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Topical rather than intradermal application of the TLR7 ligand imiquimod leads to human dermal dendritic cell maturation and CD8+ T-cell cross-priming.
    Fehres CM; Bruijns SC; van Beelen AJ; Kalay H; Ambrosini M; Hooijberg E; Unger WW; de Gruijl TD; van Kooyk Y
    Eur J Immunol; 2014 Aug; 44(8):2415-24. PubMed ID: 24825342
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Toll-like receptor 7 agonist imiquimod prevents the progression of SLE in MRL/lpr mice via inhibiting the differentiation of T follicular helper cells.
    Duan X; Shen C; Zhang X; Wu L; Chen J; Ma B; Wang Q; Sun P; Lan Y; Su C
    Int Immunopharmacol; 2020 Mar; 80():106239. PubMed ID: 32007709
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aminoglycosides can be a better choice over macrolides in COVID-19 regimen: Plausible mechanism for repurposing strategy.
    Chalichem NSS; Bethapudi B; Mundkinajeddu D
    Med Hypotheses; 2020 Nov; 144():109984. PubMed ID: 32554149
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evolution of Toll-like receptor 7/8 agonist therapeutics and their delivery approaches: From antiviral formulations to vaccine adjuvants.
    Bhagchandani S; Johnson JA; Irvine DJ
    Adv Drug Deliv Rev; 2021 Aug; 175():113803. PubMed ID: 34058283
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy.
    Broomfield SA; van der Most RG; Prosser AC; Mahendran S; Tovey MG; Smyth MJ; Robinson BW; Currie AJ
    J Immunol; 2009 May; 182(9):5217-24. PubMed ID: 19380767
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A dual and conflicting role for imiquimod in inflammation: A TLR7 agonist and a cAMP phosphodiesterase inhibitor.
    Ernst O; Failayev H; Athamna M; He H; Tsfadia Y; Zor T
    Biochem Pharmacol; 2020 Dec; 182():114206. PubMed ID: 32828805
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Topical imiquimod treatment prevents UV-light induced loss of contact hypersensitivity and immune tolerance.
    Thatcher TH; Luzina I; Fishelevich R; Tomai MA; Miller RL; Gaspari AA
    J Invest Dermatol; 2006 Apr; 126(4):821-31. PubMed ID: 16439962
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oxytocin as a potential defence against Covid-19?
    Soumier A; Sirigu A
    Med Hypotheses; 2020 Jul; 140():109785. PubMed ID: 32344303
    [No Abstract]   [Full Text] [Related]  

  • 36. Imiquimod Boosts Interferon Response, and Decreases ACE2 and Pro-Inflammatory Response of Human Bronchial Epithelium in Asthma.
    Nieto-Fontarigo JJ; Tillgren S; Cerps S; Sverrild A; Hvidtfeldt M; Ramu S; Menzel M; Sander AF; Porsbjerg C; Uller L
    Front Immunol; 2021; 12():743890. PubMed ID: 34950134
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells.
    Drobits B; Holcmann M; Amberg N; Swiecki M; Grundtner R; Hammer M; Colonna M; Sibilia M
    J Clin Invest; 2012 Feb; 122(2):575-85. PubMed ID: 22251703
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cell-type specific distribution and activation of type I IFN pathway molecules at the placental maternal-fetal interface in response to COVID-19 infection.
    Wang Y; Gu Y; Lewis DF; Gu X; Brown K; Lachute C; Hankins M; Scott RS; Busada C; Cooper DB; McCathran CE; Barrilleaux P
    Front Endocrinol (Lausanne); 2022; 13():951388. PubMed ID: 36743911
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SARS Coronavirus Papain-Like Protease Inhibits the TLR7 Signaling Pathway through Removing Lys63-Linked Polyubiquitination of TRAF3 and TRAF6.
    Li SW; Wang CY; Jou YJ; Huang SH; Hsiao LH; Wan L; Lin YJ; Kung SH; Lin CW
    Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27164085
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systemic administration of imiquimod as an adjuvant improves immunogenicity of a tumor-lysate vaccine inducing the rejection of a highly aggressive T-cell lymphoma.
    Sciullo PD; Menay F; Cocozza F; Gravisaco MJ; Waldner CI; Mongini C
    Clin Immunol; 2019 Jun; 203():154-161. PubMed ID: 31048012
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.